Dr. Jasper (Ph.D., 1988, M.I.T./Woods Hole Oceanographic Inst.).  founded and is the Chief Scientific Officer of Molecular Isotope Technologies LLC (MIT LLC) in 1999, a company that specializes in pharmaceutical product and process authentication (“Nature’s Fingerprint™”).  By training, he is an analytical organic and stable isotope chemist who uses bulk and compound-specific approaches to determine the sources of natural and synthetic organic matter and their synthetic “fingerprints,” particularly in pharmaceutical materials (MIT LLC Articles). He earned his B.A. in Geophysical Sciences and in Biological Sciences at the University of Chicago (1981).  He earned a Ph.D. in marine organic chemistry from the Massachusetts Institute of Technology/Woods Hole Oceanographic Institution Joint Program in Chemical Oceanography (1988).  In his Ph.D. thesis, he assessed the quantitative relationship between the elemental and isotopic compositions of bulk organic phases and contemporaneous specific organic compounds to understand the effects of climatic change as recorded in deep ocean sediments. As a postdoctoral fellow and scientist at the Department of Chemistry at Indiana University (1988-1994), he co-developed an isotopic method by which to reconstruct dissolved CO2 levels in ancient oceans which has been in use for at least a decade since then. (For a science-in-fictionalized account, see "Carbon Dreams" by Susan M. Gaines, 2001, Creative Arts Book Company, Berkeley, California) First in the pharmaceutical industry at Pfizer Inc. and Cultor Inc., he developed methods to separate and to quantify complex mixtures of synthetic triglycerides, methods that were employed in industrial-scale production.  By 2001 with MIT LLC, he and colleagues from both the pharmaceutical community and the U.S. Food and Drug Administration (FDA) had convincingly shown that multiple stable isotopes could be used to highly-specifically individual batches of pharmaceutical materials (Jasper, 2004 and MIT LLC Articles), showing that virtually every lot or batch of pharmaceutical products had their own "isotopic fingerprints."  In 2002, Dr. Jasper began working confidentially with Johnson & Johnson research scientists on differentiating pharmaceutical synthetic pathways by their isotopic fingerprints (published in Jasper, Weaner, and Duffy, 2005).  In 2004, he initiated the American Chemical Society’s first meeting on Pharmaceutical Authentication and Forensic Analysis (PAFA ad).  MIT LLC works with major pharmaceutical companies and the FDA, focusing on the use of stable isotopes in Pharmaceutical Product and Process Authenticity, with process-patent protection as a major area of interest.  In 2005, MIT LLC’s first patent on pharmaceutical stable-isotopic authentication was issued in Australia, with 15 more patents pending in the USA and in G7 countries.  In 2006, MIT LLC is focusing on the use of stable isotopes in process patent protection for the legal defense of its clients and has filed patents in the area of process authentication.  Dr. Jasper is a regular speaker or participant in a variety of professional meetings of the pharmaceutical International Isotope Society, Reconnaissance International, American Association of Pharmaceutical Scientists, American Chemical Society etc.  Dr. Jasper’s detailed CV can be viewed by clicking here.  Contact Dr. Jasper at either JPJasper@MolecularIsotopes.com or at JPJasper@NaturesFingerprint.com